Shopping Cart
- Remove All
Your shopping cart is currently empty
LLY-283 is a potent, selective, and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, exhibiting an IC50 of 22 nM and a Kd of 6 nM for the PRMT5:MEP50 complex, and demonstrates antitumor activity.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $34 | In Stock | |
| 5 mg | $79 | In Stock | |
| 10 mg | Preferential | In Stock | |
| 50 mg | Preferential | In Stock | |
| 1 mL x 10 mM (in DMSO) | $88 | In Stock |
| Description | LLY-283 is a potent, selective, and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, exhibiting an IC50 of 22 nM and a Kd of 6 nM for the PRMT5:MEP50 complex, and demonstrates antitumor activity. |
| Targets&IC50 | PRMT5:22 nM, MEP50:22 nM, PRMT5:(ki)6 nM, MEP50:(ki)6 nM |
| In vitro | LLY-283 is a potent, oral, and selective arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM in vitro and 25 nM in cells, and a Kd of 6 nM for the PRMT5:MEP50 complex in vitro; LLY-283 inhibits A375 cell proliferation with an IC50 of 46 nM[1]. |
| In vivo | LLY-283 administered orally at a dose of 20 mg/kg daily significantly inhibits tumor growth in A375 cell-bearing mice over a 28-day treatment period[1]. |
| Molecular Weight | 342.35 |
| Formula | C17H18N4O4 |
| Cas No. | 2040291-27-6 |
| Smiles | [H][C@@]1(O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12)[C@H](O)c1ccccc1 |
| Relative Density. | no data available |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 3.57 mg/mL (10.43 mM), Sonication and heating to 60℃ are recommended. DMSO: 112.5 mg/mL (328.6 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (11.68 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.